Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 5:00 pm Purchase |
2024-11-14 | 13G | Akari Therapeutics, Plc AKTX |
Huh Hoyoung | 8,294,508,000 15.500% |
8,294,508,000 (New Position) |
Filing History |
| 2025-02-14 5:00 pm Purchase |
2024-11-14 | 13D | Akari Therapeutics, Plc AKTX |
Prudo-Chlebosz Raymond | 4,926,600,800 9.300% |
4,926,600,800 (New Position) |
Filing History |
| 2024-12-06 4:00 pm Purchase |
2024-11-14 | 13D | Akari Therapeutics, Plc AKTX |
Patel Samir Rashmikant | 5,745,834,167 10.850% |
2,332,672,000 (+68.34%) |
Filing History |
| 2024-06-20 07:30 am Purchase |
2024-05-31 | 13D | Akari Therapeutics, Plc AKTX |
RPC Pharma Ltd | 4,507,314,800 19.200% |
1,022,356,900 (+29.34%) |
Filing History |
| 2024-06-18 4:15 pm Purchase |
2024-05-31 | 13D | Akari Therapeutics, Plc AKTX |
Theofilos Charles Steve | 2,370,750,000 9.990% |
2,370,750,000 (New Position) |
Filing History |
| 2024-06-07 6:00 pm Purchase |
2024-05-31 | 13D | Akari Therapeutics, Plc AKTX |
Patel Samir Rashmikant | 3,413,162,167 14.500% |
3,413,162,167 (New Position) |
Filing History |
| 2024-01-04 12:34 pm Purchase |
2024-01-01 | 13D | Akari Therapeutics, Plc AKTX |
RPC Pharma Ltd | 3,484,957,900 26.400% |
3,484,957,900 (New Position) |
Filing History |
| 2023-10-20 5:00 pm Purchase |
2023-10-06 | 13D | Akari Therapeutics, Plc AKTX |
RPC Pharma Ltd | 2,537,089,900 21.800% |
2,422,344,655 (+2111.06%) |
Filing History |
| 2023-04-14 4:06 pm Purchase |
2023-03-31 | 13D | Akari Therapeutics, Plc AKTX |
RPC Pharma Ltd | 114,745,245 22.700% |
68,037,935 (+145.67%) |
Filing History |
| 2023-02-14 4:05 pm Purchase |
2022-12-31 | 13G | Akari Therapeutics, Plc AKTX |
Patel Samir Rashmikant | 393,102 9.900% |
209,198 (+113.75%) |
Filing History |
| 2022-02-14 08:02 am Purchase |
2021-12-31 | 13G | Akari Therapeutics, Plc AKTX |
Patel Samir Rashmikant | 183,904 6.200% |
59,285 (+47.57%) |
Filing History |
| 2022-01-14 4:18 pm Purchase |
2021-12-29 | 13D | Akari Therapeutics, Plc AKTX |
RPC Pharma Ltd | 46,707,310 18.000% |
2,022,975 (+4.53%) |
Filing History |
| 2021-10-18 5:06 pm Purchase |
2021-07-07 | 13D | Akari Therapeutics, Plc AKTX |
RPC Pharma Ltd | 44,684,335 18.800% |
3,060,480 (+7.35%) |
Filing History |
| 2021-02-16 08:31 am Purchase |
2020-12-31 | 13G | Akari Therapeutics, Plc AKTX |
Patel Samir Rashmikant | 124,619 7.200% |
48,417 (+63.54%) |
Filing History |
| 2020-08-11 4:15 pm Sale |
2020-07-16 | 13G | Akari Therapeutics, Plc AKTX |
Shigeta Yasumitsu | 0 0.000% |
-75,005 (Position Closed) |
Filing History |
| 2020-07-02 06:21 am Purchase |
2020-07-01 | 13G | Akari Therapeutics, Plc AKTX |
Aspire Capital Fund LLC | 33,679,045 19.890% |
33,679,045 (New Position) |
Filing History |